Analysts See $0.21 EPS for Meridian Bioscience, Inc. (VIVO)

Meridian Bioscience, Inc. (NASDAQ:VIVO) Logo
Investors sentiment decreased to 1.13 in 2018 Q4. Its down 0.02, from 1.15 in 2018Q3. It is negative, as 18 investors sold Meridian Bioscience, Inc. shares while 53 reduced holdings. 34 funds opened positions while 46 raised stakes. 38.14 million shares or 2.14% more from 37.34 million shares in 2018Q3 were reported.
Barclays Public Llc reported 15,996 shares or 0% of all its holdings. Sector Pension Investment Board stated it has 37,180 shares or 0.01% of all its holdings. 279,947 were accumulated by Oregon Employees Retirement Fund. Meeder Asset Management Inc has 523 shares. First Manhattan holds 0% or 7,062 shares in its portfolio. Employees Retirement Association Of Colorado stated it has 15,374 shares or 0% of all its holdings. 32,000 were accumulated by Cambridge Inv Research. Cardinal accumulated 30,072 shares or 0.17% of the stock. Vaughan Nelson Limited Partnership reported 0.19% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO). Arizona State Retirement Sys reported 65,300 shares. Deutsche Bank Ag has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Connor Clark & Lunn Inv Ltd accumulated 22,850 shares. Eqis Management Incorporated holds 0.02% or 12,245 shares. Teachers Retirement Sys Of The State Of Kentucky holds 0% or 16,229 shares in its portfolio. Amer Gp holds 0% or 32,347 shares.

Since November 12, 2018, it had 0 insider purchases, and 1 insider sale for $681,229 activity.

Analysts expect Meridian Bioscience, Inc. (NASDAQ:VIVO) to report $0.21 EPS on April, 25.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $0.21 EPS. VIVO’s profit would be $8.92 million giving it 14.82 P/E if the $0.21 EPS is correct. After having $0.20 EPS previously, Meridian Bioscience, Inc.’s analysts see 5.00 % EPS growth. The stock decreased 1.81% or $0.23 during the last trading session, reaching $12.45. About 133,119 shares traded. Meridian Bioscience, Inc. (NASDAQ:VIVO) has risen 23.48% since April 17, 2018 and is uptrending. It has outperformed by 19.11% the S&P500.

Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide. The company has market cap of $528.99 million. The firm operates through Diagnostics and Life Science divisions. It has a 20.75 P/E ratio. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More notable recent Meridian Bioscience, Inc. (NASDAQ:VIVO) news were published by: Globenewswire.com which released: “Harvard Bioscience To Showcase Products at Experimental Biology 2019 – GlobeNewswire” on March 26, 2019, also Nasdaq.com with their article: “Meridian Bioscience Inc. (VIVO) Ex-Dividend Date Scheduled for February 01, 2019 – Nasdaq” published on January 31, 2019, Nasdaq.com published: “Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting – Nasdaq” on April 01, 2019. More interesting news about Meridian Bioscience, Inc. (NASDAQ:VIVO) were released by: Nasdaq.com and their article: “Kaleido Biosciences Announces Upcoming Presentations at the Society for Inherited Metabolic Disorders Annual Meeting and The International Liver Congressâ„¢ (EASL) – Nasdaq” published on March 27, 2019 as well as Globenewswire.com‘s news article titled: “CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia – GlobeNewswire” with publication date: April 16, 2019.

Meridian Bioscience, Inc. (NASDAQ:VIVO) Institutional Positions Chart